How are ABT strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ABT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 33.21%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$362.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a ABT strangle?

The breakeven for the ABT strangle priced on this page is roughly $84.38 and $101.63 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABT market-implied 1-standard-deviation expected move is approximately 9.52%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current ABT implied volatility affect this strangle?

ABT ATM IV is at 33.21% with IV rank near 90.39%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.

ABT Strangle Strategy

ABT (Abbott Laboratories), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents.

ABT (Abbott Laboratories) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $163.42B, a trailing P/E of 26.12, a beta of 0.62 versus the broader market, a 52-week range of 81.97-137.49, average daily share volume of 13.0M, a public-listing history dating back to 1980, approximately 114K full-time employees. These structural characteristics shape how ABT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.62 indicates ABT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. ABT pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a strangle on ABT?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current ABT snapshot

As of June 29, 2026, spot at $92.87, ATM IV 33.21%, IV rank 90.39%, expected move 9.52%. The strangle on ABT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 32-day expiry.

Why this strangle structure on ABT specifically: ABT IV at 33.21% is rich versus its 1-year range, which makes a premium-buying ABT strangle relatively expensive in absolute-cost terms, with a market-implied 1-standard-deviation move of approximately 9.52% (roughly $8.84 on the underlying). The 32-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABT should anchor to the underlying notional of $92.87 per share and to the trader's directional view on ABT stock.

ABT strangle setup

The ABT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABT near $92.87, the first option leg uses a $98.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABT chain at a 32-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABT shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$98.00	$1.85
Buy 1	Put	$88.00	$1.78

ABT strangle risk and reward

Net Premium / Debit: -$362.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$362.50
Breakeven(s): $84.38, $101.63
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ABT strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ABT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$8,436.50
$20.54	-77.9%	+$6,383.20
$41.08	-55.8%	+$4,329.91
$61.61	-33.7%	+$2,276.61
$82.14	-11.6%	+$223.31
$102.67	+10.6%	+$104.98
$123.21	+32.7%	+$2,158.28
$143.74	+54.8%	+$4,211.58
$164.27	+76.9%	+$6,264.87
$184.81	+99.0%	+$8,318.17

When traders use strangle on ABT

Strangles on ABT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABT chain.

ABT thesis for this strangle

The market-implied 1-standard-deviation range for ABT extends from approximately $84.03 on the downside to $101.71 on the upside. A ABT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ABT IV rank near 90.39% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on ABT at 33.21%. As a Healthcare name, ABT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABT-specific events.

ABT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABT alongside the broader basket even when ABT-specific fundamentals are unchanged. Always rebuild the position from current ABT chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ABT?: A strangle on ABT is the strangle strategy applied to ABT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ABT stock trading near $92.87, the strikes shown on this page are snapped to the nearest listed ABT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ABT strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ABT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 33.21%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$362.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ABT strangle?: The breakeven for the ABT strangle priced on this page is roughly $84.38 and $101.63 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABT market-implied 1-standard-deviation expected move is approximately 9.52%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ABT?: Strangles on ABT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABT chain.
How does current ABT implied volatility affect this strangle?: ABT ATM IV is at 33.21% with IV rank near 90.39%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.